UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
____________________
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  November 1, 2011
 
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
001-33137
14-1902018
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

 
2273 Research Boulevard, Suite 400, Rockville, Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s telephone number, including area code:  (301) 795-1800
 
Not applicable
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 

 


Item 1.01. Entry into a Material Definitive Agreement.

On November 1, 2011, Emergent BioSolutions Inc. (the “Company”) entered into an amendment (the “Amendment”) to a consulting services agreement dated effective April 1, 2011 with The Hauer Group (the “Consulting Services Agreement”).  The Amendment provides for the termination of the Consulting Services Agreement effective at 5:00 p.m. on November 1, 2011.  The terms of the Consulting Services Agreement were previously reported in the Company’s Current Report on Form 8-K dated April 6, 2011, which Form 8-K is incorporated by reference into this Item 1.01.  The Company has no further liability to The Hauer Group as a result of the termination of the Consulting Services Agreement.

 
 

 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
Date:  November 3, 2011
EMERGENT BIOSOLUTIONS INC.
 
By:
/s/Jay G. Reilly
Jay G. Reilly
General Counsel